Ogorek Anthony Joseph NY ADV Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Ogorek Anthony Joseph NY ADV cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 97.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 916 shares of the biopharmaceutical company's stock after selling 36,812 shares during the period. Ogorek Anthony Joseph NY ADV's holdings in Pfizer were worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. King Luther Capital Management Corp grew its holdings in Pfizer by 0.6% during the 4th quarter. King Luther Capital Management Corp now owns 2,011,016 shares of the biopharmaceutical company's stock valued at $57,897,000 after purchasing an additional 11,863 shares during the last quarter. InterOcean Capital Group LLC raised its holdings in shares of Pfizer by 5.3% in the fourth quarter. InterOcean Capital Group LLC now owns 25,864 shares of the biopharmaceutical company's stock worth $745,000 after buying an additional 1,291 shares during the period. Seven Mile Advisory lifted its stake in shares of Pfizer by 5.4% during the 4th quarter. Seven Mile Advisory now owns 10,455 shares of the biopharmaceutical company's stock worth $301,000 after acquiring an additional 536 shares during the last quarter. Loews Corp bought a new position in Pfizer in the 4th quarter valued at $8,637,000. Finally, Certified Advisory Corp increased its stake in Pfizer by 1.4% in the fourth quarter. Certified Advisory Corp now owns 64,873 shares of the biopharmaceutical company's stock worth $1,868,000 after purchasing an additional 887 shares during the period. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PFE shares. BMO Capital Markets reissued an "outperform" rating and set a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Argus lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a "buy" rating and a $36.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 2nd. Ten equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $35.86.

Pfizer Stock Up 0.1 %

Shares of PFE traded up $0.03 during mid-day trading on Tuesday, hitting $28.56. 28,082,161 shares of the company traded hands, compared to its average volume of 42,523,328. The business has a 50 day moving average of $27.21 and a 200 day moving average of $27.98. The company has a market capitalization of $161.84 billion, a PE ratio of -473.75, a price-to-earnings-growth ratio of 1.21 and a beta of 0.63. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts' expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the business posted $1.23 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.39 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.88%. Pfizer's payout ratio is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.